Market Analysis

The global market for Polycystic Ovary Syndrome (PCOS) treatment is experiencing steady growth, driven by rising prevalence, greater awareness, and advances in treatment options. In 2023, market size estimates range from about $2.6 billion to $6.16 billion, with forecasts projecting growth to between $3.8 billion and $9.81 billion by 2030–31.

Competitive Analysis

The landscape of care tends to focus on diagnostics and treating individual symptoms, with little emphasis on a holistic approach. This gap gets even bigger between for-profits, non-profits, and grant-funded efforts. For-profit entities often prioritize efficiency and revenue-generating services, while non-profits and grant-funded efforts may focus on underserved populations but struggle with sustainability, leading to inconsistent implementation of holistic care models.

Diagnosis

Thermo Fisher Scientific, Quest Diagnostics, Siemens Healthineers, Abbott Laboratories, PCOS Challenge, PCOS Awareness Association, NIH Research Grants, Verity, Androgen Excess-PCOS Society Research Grant, and PCOS Challenge Research Grant.

Treatment

Bayer AG, Merck & Co., Pfizer Inc., Sanofi, Novartis AG, Novo Nordisk, Vitrolife, Abbvie Inc., Ferring Pharmaceuticals, EMD Serono, Noom, Galderma, AstraZeneca, Myriad Genetics, NIH Obesity Research Grants, L'Oreal, American Diabetes Association, Obesity Society, ASRM Research Grants, American Academy of Dermatology, American Society for Reproductive Medicine, and Endocrine Society.

Business Plan

Cyst(Her)’s business plan is to begin on a small scale, providing personalized support to women through science-based resources, awareness campaigns, and direct assistance. Our initial focus is on creating meaningful, individual-level impact. Over the next five years, we aim to scale our operations significantly, expanding our reach and infrastructure to serve a broader population while maintaining the integrity of our mission.